Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology - 1 Jan 2018

Zhao Yinghao, Yang Wei, Huang Yuanyuan, Cui Ranji, Li Xiangyan, Li Bingjin

Abstract excerpt

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activated effector T cells (Teffs) and participates in the repression of T cell proliferation, cell cycle progression and cytokine production. Currently, antibodies targeting CTLA-4, ipilimumab and tremelimumab are widely used as a therapeutic approach in a variety of human malignancies. However, their detailed mechanism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to CTLA-4 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Programmed Cell Death 1 Receptor

Share to T-Lymphocytes

Source

Identifiers

PMID: 29794465
DOI: 10.1159/000490025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.PMID 29794465Read ↗

The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.Semantic proximity Read ↗

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and TherapySemantic proximity Read ↗

Immune Checkpoint Inhibitors to Treat Malignant LymphomasSemantic proximity Read ↗

The outstanding antitumor capacity of CD4+ T helper lymphocytesSemantic proximity Read ↗

Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunitySemantic proximity Read ↗

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4Semantic proximity Read ↗

VISTA: A Promising Target for Cancer Immunotherapy?Semantic proximity Read ↗

Regulatory mechanisms of PD-1/PD-L1 in cancersSemantic proximity Read ↗

PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.Semantic proximity Read ↗

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read ↗

A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetSemantic proximity Read ↗

The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and SurvivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.